Callitas Health Inc. Aktie Canadian Securities Exchange
Aktien
A2GSU1
CA13125C1068
LILY
Biotechnologie
Umsatz 2018 | 0.75 1.02 0.69 | Umsatz 2019 | 0.71 0.97 0.65 | Marktwert | 3.53 Mio. 4.82 Mio. 3.22 Mio. |
---|---|---|---|---|---|
Nettoergebnis 2018 | -5 Mio. -6.83 Mio. -4.57 Mio. | Nettoergebnis 2019 | -1 Mio. -1.37 Mio. -914’090 | EV / Sales 2018 | 4’852’616 x |
Nettoschuld 2018 | 318’990 435’581 291’586 | Nettoschuld 2019 | 847’693 1.16 Mio. 774’868 | EV / Sales 2019 | 6’168’166 x |
KGV 2018 |
-0.6
x | KGV 2019 |
-1.97
x | Beschäftigte | - |
Rendite 2018 * |
-
| Rendite 2019 |
-
| Streubesitz | 72.04% |
Manager | Titel | Alter | Seit |
---|---|---|---|
Chief Executive Officer | - | 03.01.18 | |
Robert Payment
DFI | Director of Finance/CFO | 42 | - |
Brian Keane
BRD | Director/Board Member | 47 | - |
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
Donald Skeith
BRD | Director/Board Member | 69 | 01.12.14 |
William Rodgers
BRD | Director/Board Member | - | - |
Brian Keane
BRD | Director/Board Member | 47 | - |
% 1. Jan. | Kap. | |
---|---|---|
+60.85% | 55.07 Mrd. | |
-1.64% | 41.79 Mrd. | |
+44.36% | 40.22 Mrd. | |
-8.29% | 28.17 Mrd. | |
+12.16% | 26.28 Mrd. | |
-20.65% | 18.93 Mrd. | |
+7.06% | 13.03 Mrd. | |
+28.46% | 12.26 Mrd. | |
+26.44% | 12.21 Mrd. |